Cornerstone Wealth Group LLC boosted its position in The Clorox Company (NYSE:CLX - Free Report) by 19.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,582 shares of the company's stock after purchasing an additional 4,085 shares during the period. Cornerstone Wealth Group LLC's holdings in Clorox were worth $3,767,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Redwood Park Advisors LLC purchased a new position in Clorox in the 4th quarter valued at approximately $26,000. Millstone Evans Group LLC purchased a new position in shares of Clorox in the fourth quarter valued at $31,000. Wood Tarver Financial Group LLC bought a new stake in shares of Clorox during the 4th quarter valued at $31,000. GKV Capital Management Co. Inc. purchased a new stake in Clorox during the 4th quarter worth about $32,000. Finally, Aster Capital Management DIFC Ltd purchased a new stake in Clorox during the 4th quarter worth about $33,000. 78.53% of the stock is owned by hedge funds and other institutional investors.
Clorox Trading Down 0.2%
Shares of NYSE CLX traded down $0.22 during midday trading on Tuesday, reaching $122.08. The company had a trading volume of 1,380,581 shares, compared to its average volume of 1,556,455. The stock has a market cap of $15.05 billion, a PE ratio of 21.92, a price-to-earnings-growth ratio of 2.73 and a beta of 0.54. The Clorox Company has a one year low of $120.33 and a one year high of $171.37. The firm's fifty day moving average price is $132.74 and its 200-day moving average price is $146.30. The company has a quick ratio of 0.44, a current ratio of 0.74 and a debt-to-equity ratio of 13.07.
Clorox (NYSE:CLX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a net margin of 9.89% and a return on equity of 324.23%. The company had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.74 billion. During the same quarter in the previous year, the firm posted $1.71 EPS. The business's revenue for the quarter was down 8.0% compared to the same quarter last year. On average, equities research analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several research analysts have commented on CLX shares. UBS Group cut their price target on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. JPMorgan Chase & Co. reduced their target price on Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a research report on Tuesday, May 6th. Barclays lowered their price target on Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a report on Wednesday, May 7th. Wells Fargo & Company decreased their price objective on shares of Clorox from $145.00 to $142.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Finally, Morgan Stanley cut their price target on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, Clorox presently has an average rating of "Hold" and a consensus target price of $151.23.
Get Our Latest Analysis on CLX
Insider Activity
In related news, Director Pierre R. Breber bought 4,000 shares of the company's stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average cost of $136.57 per share, with a total value of $546,280.00. Following the transaction, the director now owns 4,000 shares in the company, valued at approximately $546,280. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.57% of the company's stock.
About Clorox
(
Free Report)
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
Featured Articles
Before you consider Clorox, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.
While Clorox currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
